NHS head and neck cancer patients barred from Opdivo

11th April 2017 Uncategorised 0

Cost regulators have ruled that Bristol-Myers Squibb’s immunotherapy Opdivo is too expensive for NHS use to treat head and neck cancer, despite the offer of Patient Access Scheme to increase the drug’s cost-effectiveness.

More: NHS head and neck cancer patients barred from Opdivo
Source: News